Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics cash
Cash and short-term investments held at the end of each period.
Protalix BioTherapeutics's cash was $27.42M at Jun 30, 2026. For fiscal 2025 it was $14.68M, down 25.7% from the year before. Over ten years it grew -15.2% a year on average. The highest annual figure on record is $86.40M in fiscal 2013.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.68M | -25.7% |
| FY2024 | Dec 31, 2024 | $19.76M | -16.4% |
| FY2023 | Dec 31, 2023 | $23.63M | +38.1% |
| FY2022 | Dec 31, 2022 | $17.11M | -56.1% |
| FY2021 | Dec 31, 2021 | $38.99M | +113.4% |
| FY2020 | Dec 31, 2020 | $18.27M | +2.7% |
| FY2019 | Dec 31, 2019 | $17.79M | -52.9% |
| FY2018 | Dec 31, 2018 | $37.81M | -26.1% |
| FY2017 | Dec 31, 2017 | $51.16M | -19.1% |
| FY2016 | Dec 31, 2016 | $63.28M | -17.1% |
| FY2015 | Dec 31, 2015 | $76.37M | +39.5% |
| FY2014 | Dec 31, 2014 | $54.77M | -36.6% |
| FY2013 | Dec 31, 2013 | $86.40M | +66.0% |
| FY2012 | Dec 31, 2012 | $52.04M | +92.7% |
| FY2011 | Dec 31, 2011 | $27.00M | -24.8% |
| FY2010 | Dec 31, 2010 | $35.90M | -55.8% |
| FY2009 | Dec 31, 2009 | $81.27M | +90.8% |
| FY2008 | Dec 31, 2008 | $42.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.42M | +53.2% |
| Q1 FY2026 | Mar 31, 2026 | $41.00M | +110.7% |
| Q4 FY2025 | Dec 31, 2025 | $14.68M | -25.7% |
| Q3 FY2025 | Sep 30, 2025 | $13.65M | -50.2% |
| Q2 FY2025 | Jun 30, 2025 | $17.90M | -23.5% |
| Q1 FY2025 | Mar 31, 2025 | $19.46M | -28.5% |
| Q4 FY2024 | Dec 31, 2024 | $19.76M | -16.4% |
| Q3 FY2024 | Sep 30, 2024 | $27.41M | +34.3% |
| Q2 FY2024 | Jun 30, 2024 | $23.40M | -51.4% |
| Q1 FY2024 | Mar 31, 2024 | $27.21M | -17.6% |
| Q4 FY2023 | Dec 31, 2023 | $23.63M | +38.1% |
| Q3 FY2023 | Sep 30, 2023 | $20.41M | +90.4% |
| Q2 FY2023 | Jun 30, 2023 | $48.18M | +285.7% |
| Q1 FY2023 | Mar 31, 2023 | $33.04M | +95.6% |
| Q4 FY2022 | Dec 31, 2022 | $17.11M | -56.1% |
| Q3 FY2022 | Sep 30, 2022 | $10.72M | +0.7% |
| Q2 FY2022 | Jun 30, 2022 | $12.49M | -63.1% |
| Q1 FY2022 | Mar 31, 2022 | $16.89M | -14.8% |
| Q4 FY2021 | Dec 31, 2021 | $38.99M | +113.4% |
| Q3 FY2021 | Sep 30, 2021 | $10.64M | -21.4% |
| Q2 FY2021 | Jun 30, 2021 | $33.88M | +139.2% |
| Q1 FY2021 | Mar 31, 2021 | $19.83M | +11.5% |
| Q4 FY2020 | Dec 31, 2020 | $18.27M | -14.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.53M | -46.1% |
| Q1 FY2020 | Mar 31, 2020 | $14.17M | -53.3% |
| Q4 FY2019 | Dec 31, 2019 | $17.79M | -52.9% |
| Q3 FY2019 | Sep 30, 2019 | $21.44M | -48.8% |
| Q2 FY2019 | Jun 30, 2019 | $25.10M | -11.4% |
| Q1 FY2019 | Mar 31, 2019 | $30.36M | -26.5% |
| Q4 FY2018 | Dec 31, 2018 | $37.81M | -26.1% |
| Q3 FY2018 | Sep 30, 2018 | $41.87M | +25.0% |
| Q2 FY2018 | Jun 30, 2018 | $28.33M | -18.0% |
| Q1 FY2018 | Mar 31, 2018 | $41.32M | -13.9% |
| Q4 FY2017 | Dec 31, 2017 | $51.16M | -19.1% |
| Q3 FY2017 | Sep 30, 2017 | $33.48M | -34.8% |
| Q2 FY2017 | Jun 30, 2017 | $34.53M | -36.8% |
| Q1 FY2017 | Mar 31, 2017 | $48.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.32M | – |
| Q2 FY2016 | Jun 30, 2016 | $54.63M | – |
See a number that looks wrong?